Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.23
-2.6%
$7.91
$5.01
$18.71
$55.02M0.18117,258 shs23,402 shs
Cellectis S.A. stock logo
CLLS
Cellectis
$1.59
-3.6%
$1.49
$1.10
$2.43
$88.37M2.91142,976 shs17,240 shs
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
$20.01
$20.00
$4.95
$20.68
$957.54M-0.94847,595 shs1 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$21.77
+3.8%
$14.08
$10.80
$22.32
$315.23M-0.0497,590 shs62,977 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$148.17
-1.0%
$136.18
$122.80
$219.34
$4.28B0.67287,895 shs267,497 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+2.71%+18.35%+3.95%+71.43%+5.10%
Cellectis S.A. stock logo
CLLS
Cellectis
+1.54%+4.10%+17.02%+14.58%-15.38%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
0.00%0.00%0.00%0.00%0.00%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
+0.29%+28.83%+36.50%+80.71%+61.76%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.56%+4.71%+8.34%-9.25%-22.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.1273 of 5 stars
3.33.00.04.70.62.50.6
Cellectis S.A. stock logo
CLLS
Cellectis
3.1437 of 5 stars
3.53.00.00.02.62.50.6
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.8776 of 5 stars
0.01.00.04.61.92.51.3
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.5857 of 5 stars
3.51.00.04.72.92.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.57
Moderate Buy$17.7590.25% Upside
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.00146.15% Upside
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
0.00
N/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$213.7544.17% Upside

Current Analyst Ratings Breakdown

Latest ATRA, KRYS, FMTX, CLLS, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.00
6/24/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
5/16/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/15/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$195.00 ➝ $189.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$219.00 ➝ $219.00
5/6/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00 ➝ $240.00
4/28/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$221.00 ➝ $240.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$199.73M0.28N/AN/A($16.89) per share-0.55
Cellectis S.A. stock logo
CLLS
Cellectis
$49.22M1.83N/AN/A$2.36 per share0.69
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
$100.56M9.52N/AN/A$10.51 per share1.90
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,599.46$122.73 per share0.18$9.23 per share2.39
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$290.52M14.75$4.62 per share32.11$32.90 per share4.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B$116.750.19N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.1635.6614.71N/A37.17%14.64%13.28%8/4/2025 (Estimated)

Latest ATRA, KRYS, FMTX, CLLS, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025N/A
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.15N/AN/AN/A$10.07 millionN/A
8/4/2025Q2 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.20N/AN/AN/A$95.42 millionN/A
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
5/14/2025Q4 2024
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.57
0.57
Cellectis S.A. stock logo
CLLS
Cellectis
0.44
1.67
1.67
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/A
12.74
12.74
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.04
5.12
5.12
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.65
9.27

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
87.39%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%

Insider Ownership

CompanyInsider Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.00%
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
5.79%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
17.09%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.72 millionOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
16647.85 million45.08 millionNot Optionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 million12.00 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.94 millionOptionable

Recent News About These Companies

Q2 EPS Estimates for Krystal Biotech Decreased by Analyst
High Insider Ownership In 3 Promising Growth Companies
Analysts Offer Predictions for Krystal Biotech Q2 Earnings
FY2026 EPS Estimates for Krystal Biotech Reduced by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$9.23 -0.25 (-2.64%)
Closing price 04:00 PM Eastern
Extended Trading
$9.25 +0.02 (+0.22%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.59 -0.06 (-3.64%)
Closing price 04:00 PM Eastern
Extended Trading
$1.55 -0.04 (-2.52%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Forma Therapeutics stock logo

Forma Therapeutics NASDAQ:FMTX

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$21.77 +0.79 (+3.77%)
Closing price 04:00 PM Eastern
Extended Trading
$21.74 -0.02 (-0.11%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$148.17 -1.57 (-1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$149.57 +1.40 (+0.94%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.